Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04530461

Enrollment

200

Registered

2020-08-28

Start date

2020-06-01

Completion date

2021-01-31

Last updated

2020-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV Infection, Systemic Disease, Systemic Lupus Erythematosus, Sjogren's Syndrome, Sarcoidosis, Inflammatory Myopathy, Behçet Disease, Rheumatoid Arthritis, Spondyloarthritis

Brief summary

An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis

Detailed description

The study is a prospective, observational, multicenter clinical trial to be conducted in the internal medicine, rheumatology and virology departments of Military Hospital of Tunis. After obtaining informed consent from the patient, the investigator will perform an inclusion visit made of a patient interview and performing blood sample to search for IgG and anti-SARS IgM CoV2. Patients with IgM-like antibodies will have an RT-PCR test for active infection. If the study participants will be diagnosed with COVID-19 positive during the study period, the attending physician is entitled to decide on their management based on the severity of the clinical status.

Interventions

DIAGNOSTIC_TESTSerological test

Positive serological test of SARS Cov2

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age over 18 years old * One of the following conditions: systemic lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory myopathies, spondyloarthritis, sarcoidosis and Behçet's disease. * Informed consent obtained and signed

Exclusion criteria

* Refusal to repeat blood sampling if the first one was badly performed * Informed consent not obained

Design outcomes

Primary

Measure	Time frame	Description
Serological Profile	Inclusion	Number of patients with positive serological test of SARS Cov2

Countries

Tunisia

Contacts

Primary ContactFaida Ajili, MD

faida1977@yahoo.fr+21698631188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026